References
- Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea K S, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439–442
- Gerber H P, Malik A K, Solar G P, Sherman D, Liang X H, Meng G, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954–958
- Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. Journal of Clinical Investigations 2000; 106: 511–521
- Bellamy W T, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427–1434
- Santos S C, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute Leukemia through distinct signaling pathways. Blood 2004; 103: 3883–3889
- List A F, Glinsmann-Gibson B, Stadheim C, Meuillet E J, Bellamy W, Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Experimental Hematology 2004; 32: 526–535
- Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proceedings of the National Academy of Sciences (USA) 2001; 98: 10857–10862
- Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717–3721
- de Bont E S, Rosati S, Jacobs S, Kamps W A, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. British Journal of Haematology 2001; 113: 296–304
- de Bont E S, Fidler V, Meeuwsen T, Scherpen F, Hahlen K, Kamps W A. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clinical Cancer Research 2002; 8: 2856–2861
- Frankel A E, Gill P S. VEGF and myeloid leukemias. Leukemia Research 2004; 28: 675–677
- Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003; 102: 2763–2767
- Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann O G, O'Farrell A M, et al. A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986–993
- Karp J E, Gojo I, Pili R, Gocke C D, Greer J, Guo C, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research 2004; 10: 3577–3585
- Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld D K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870–1875
- Green C J, Lichtlen P, Huynh N T, Yanovsky M, Laderoute K R, Schaffner W, Murphy B J. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Research 2001; 61: 2696–2703
- Herold-Mende C, Steiner H H, Andl T, Riede D, Buttler A, Reisser C, et al. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Laboratory Investigations 1999; 79: 1573–1582
- Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T. Molecular structure of the human cytoplasmic β-actin gene. Proceedings of the National Academy of Sciences (USA) 1985; 82: 6133–6137
- Watarai M, Miwa H, Shikami M, Sugamura K, Wakabayashi M, Satoh A, et al. Expression of endothelial cell-associated molecules in AML cells. Leukemia 2002; 16: 112–119
- Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004; 103: 3644–3654